Wedbush initiated coverage of Sana Biotechnology (SANA) with an Outperform rating and $5 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA:
- Sana Biotechnology Announces Leadership Transition
- Sana Biotechnology Board Member Resigns Effective August 29
- Sana Biotechnology Reports Q2 2025 Financial Results
- Sana Biotechnology’s Strategic Advances and Positive FDA Feedback Bolster Buy Rating
- Sana Biotechnology’s Promising Advances in Diabetes Treatment and Strong Financial Position Support Buy Rating